Advertisement
Research Article

Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates

  • Thomas W. Geisbert mail,

    geisbert@bu.edu

    Affiliations: National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, United States of America, Department of Microbiology, Boston University School of Medicine, Boston, Massachusetts, United States of America, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States of America, Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America, Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, Virology Division, BIOQUAL, Rockville, Maryland, United States of America

    X
  • Kathleen M. Daddario-DiCaprio,

    Affiliations: National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, United States of America, Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America, Virology Division, BIOQUAL, Rockville, Maryland, United States of America

    X
  • Mark G. Lewis,

    Affiliation: BIOQUAL, Rockville, Maryland, United States of America

    X
  • Joan B. Geisbert,

    Affiliations: National Emerging Infectious Diseases Laboratories Institute, Boston, Massachusetts, United States of America, Virology Division, BIOQUAL, Rockville, Maryland, United States of America

    X
  • Allen Grolla,

    Affiliation: BIOQUAL, Rockville, Maryland, United States of America

    X
  • Anders Leung,

    Affiliation: Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada

    X
  • Jason Paragas,

    Affiliation: Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Lennox Matthias,

    Affiliation: BIOQUAL, Rockville, Maryland, United States of America

    X
  • Mark A. Smith,

    Affiliation: Pathology Division, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, United States of America

    X
  • Steven M. Jones,

    Affiliations: Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada, Department of Immunology, University of Manitoba, Winnipeg, Manitoba, Canada, Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada

    X
  • Lisa E. Hensley,

    Affiliation: Virology Division, BIOQUAL, Rockville, Maryland, United States of America

    X
  • Heinz Feldmann,

    Affiliations: Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada, Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada

    Current address: Laboratory of Virology, Division of Intramural Research, National Institutes of Allergy and Infectious Diseases Rocky Mountain Laboratories, Hamilton, Montana, United States of America

    X
  • Peter B. Jahrling

    Affiliations: Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, Emerging Viral Pathogens Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America

    X
  • Published: November 28, 2008
  • DOI: 10.1371/journal.ppat.1000225

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.